Press Releases Johnson & Johnson Deutsche Boerse AG

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 03:08:42 2024-07-01 EDT			5-day change	1st Jan Change
136.3 ^EUR	-0.37%		-1.73%	-3.74%

06-28	Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	MT
06-28	J&J Unit's Rybrevant Combo Gets EU Approval	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	06-28	PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	06-28	PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	06-28	PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	06-27	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	06-27	AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	06-25	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	06-24	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	06-21	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	06-21	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	06-20	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	06-20	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	06-20	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	06-18	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	06-17	BU
J&J commits five-year investment in Italian medicine manufacturing	06-17	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	06-17	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	06-17	AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	06-15	PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	06-14	PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	06-14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm